The DOI matches its Crossref record; 426 of the 426 references it cites were found in a registry or an index.
Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment
Open accessAbstract
Several immune and immunocompetent cells, including dendritic cells, macrophages, adipocytes, natural killer cells, T cells, and B cells, are significantly correlated with the complex discipline of oncology. Cytotoxic innate and adaptive immune cells can block tumor proliferation, and others can prevent the immune system from rejecting malignant cells and provide a favorable environment for tumor progression. These cells communicate with the microenvironment through cytokines, a chemical messenger, in an endocrine, paracrine, or autocrine manner. These cytokines play an important role in health and disease, particularly in host immune responses to infection and inflammation. They include chemokines, interleukins (ILs), adipokines, interferons, colony-stimulating factors (CSFs), and tumor necrosis factor (TNF), which are produced by a wide range of cells, including immune cells, such as macrophages, B-cells, T-cells, and mast cells, as well as endothelial cells, fibroblasts, a variety of stromal cells, and some cancer cells. Cytokines play a crucial role in cancer and cancer-related inflammation, with direct and indirect effects on tumor antagonistic or tumor promoting functions. They have been extensively researched as immunostimulatory mediators to promote the generation, migration and recruitment of immune cells that contribute to an effective antitumor immune response or pro-tumor microenvironment. Thus, in many cancers such as breast cancer, cytokines including leptin, IL-1B, IL-6, IL-8, IL-23, IL-17, and IL-10 stimulate while others including IL-2, IL-12, and IFN-γ, inhibit cancer proliferation and/or invasion and enhance the body’s anti-tumor defense. Indeed, the multifactorial functions of cytokines in tumorigenesis will advance our understanding of cytokine crosstalk pathways in the tumor microenvironment, such as JAK/STAT, PI3K, AKT, Rac, MAPK, NF-κB, JunB, cFos, and mTOR, which are involved in angiogenesis, cancer proliferation and metastasis. Accordingly, targeting and blocking tumor-promoting cytokines or activating and amplifying tumor-inhibiting cytokines are considered cancer-directed therapies. Here, we focus on the role of the inflammatory cytokine system in pro- and anti-tumor immune responses, discuss cytokine pathways involved in immune responses to cancer and some anti-cancer therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 401–426 of 426
Dynamic control of lymphocyte trafficking by fever-range thermal stress
Chen, Q., Fisher, D. T., Kucinska, S. A., et al. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0022-9 · Cited by 38
IL-12 induces autophagy in human breast cancer cells through AMPK and the PI3K/Akt pathway
Lin, Y., Kuang, W., Wu, B., Xie, C., Liu, C., & Tu, Z. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7114 · Cited by 38
Aberrant expression of IL-23/IL-23R in patients with breast cancer and its clinical significance
Sheng, S., Zhang, J., Ai, J., Hao, X., & Luan, R. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8427 · Cited by 38
Chen, H., Chou, A. S., Liu, Y., Hsieh, C.-H., Kang, C.-C., Pang, S., Yeh, C., Liu, H.-P., & Liao, S.-K. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.91 · Cited by 37
Hao, Q., & Tang, H. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0579-y · Cited by 37
Li, S., Wei, X., Zhan, X., He, J., Zeng, Y.-Q., Tian, X., Yuan, S., & Sun, L. (2020) · Cancers · doi:10.3390/cancers12123864 · Cited by 37
Rivas, M. A., Tkach, M., Béguelin, W., Proietti, C. J., Rosemblit, C., Charreau, E. H., Elizalde, P. V., & Schillaci, R. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0546-3 · Cited by 35
IL‐10 suppresses TNF‐α‐induced expression of human aromatase gene in mammary adipose tissue
Martínez‐Chacón, G., Brown, K. A., Docanto, M. M., Kumar, H., Salminen, S., Saarinen, N., & Mäkelä, S. (2018) · The FASEB Journal · doi:10.1096/fj.201700938rrr · Cited by 35
Gagro, A., Servis, D., Cepika, A., Toellner, K., Grafton, G., Taylor, D. R., Branica, S., & Gordon, J. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02342.x · Cited by 34
Gelsomino, L., Naimo, G. D., Malivindi, R., Augimeri, G., Panza, S., Giordano, C., Barone, I., Bonofiglio, D., Mauro, L., Catalano, S., et al. (2020) · Cancers · doi:10.3390/cancers12082078 · Cited by 34
Interleukin-17 Cytokines and Receptors: Potential Amplifiers of Tendon Inflammation
Mimpen, J. Y., Snelling, S. J. B., Carr, A. J., & Dakin, S. G. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.795830 · Cited by 34
Interleukin-6 enhances motility of breast carcinoma cells
Sehgal, P. B., & Tamm, I. (1991) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-7494-6_12 · Cited by 31
Targeting IL-23 in human diseases
D’Elios, M. M., Prete, G. D., & Amedei, A. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.497143 · Cited by 30
Targeted Activation of T Cells with IL-2-Coupled Nanoparticles
Raker, V., Becker, C., Landfester, K., & Steinbrink, K. (2020) · Cells · doi:10.3390/cells9092063 · Cited by 29
Omi, K., Matsuo, Y., Ueda, G., Aoyama, Y., Kato, T., Hayashi, Y., Imafuji, H., Saito, K., Tsuboi, K., Morimoto, M., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8006 · Cited by 27
Effects of ulinastatin and docataxel on breast tumor growth and expression of IL-6, IL-8, and TNF-α
Zhao, X., Sun, X., Gao, F., Luo, J., & Sun, Z. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-22 · Cited by 24
Delort, L., Cholet, J., Decombat, C., Vermerie, M., Dumontet, C., Castelli, F. A., Fenaille, F., Auxenfans, C., Rossary, A., & Caldefie‐Chezet, F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.571948 · Cited by 24
Self-citationInducible IFN-γ Expression for MHC-I Upregulation in Devil Facial Tumor Cells
Ong, C. E. B., Lyons, A. B., Woods, G. M., & Flies, A. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03117 · Cited by 22
Innate lymphoid cells involve in tumorigenesis
Tian, Z., van Velkinburgh, J. C., Wu, Y., & Ni, B. (2015) · International Journal of Cancer · doi:10.1002/ijc.29443 · Cited by 20
Leptin in Tumor Microenvironment
Angelucci, A., Clementi, L., & Alesse, E. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43093-1_6 · Cited by 18
WNT5A augments cell invasiveness by inducing CXCL8 in HER2-positive breast cancer cells
Kim, S., You, D., Jeong, Y., Yoon, S. Y., Kim, S. A., Kim, S. W., Nam, S. J., & Lee, J. E. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155213 · Cited by 15
Panneerselvam, J., Madka, V., Rai, R., Morris, K. T., Houchen, C. W., Chandrakesan, P., & Rao, C. V. (2021) · Cancers · doi:10.3390/cancers13205159 · Cited by 14
Morrow, R. J., Allam, A. H., Yeo, B. J., Deb, S., Murone, C., Lim, E., Johnstone, C. N., & Ernst, M. (2022) · Cancers · doi:10.3390/cancers14092292 · Cited by 13
Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer
Jiang, X. (2015) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1400352 · Cited by 11
Olson, M. R., Russ, B. E., Doherty, P. C., & Turner, S. J. (2010) · IUBMB Life · doi:10.1002/iub.351 · Cited by 8
Tsuchihashi (2000) · doi:10.1002/1521-4141(200006)30:6
Cited by
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Metadata
- Authors
- Habanjar, O., Bingula, R., Decombat, C., Diab-Assaf, M., Caldefie-Chezet, F., & Delort, L.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-02-16
- Volume
- 24
- Issue
- 4
- Pages
- 4002
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4321092565
- Cited by
- 263
- References
- 426
- FWCI
- 23.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.